Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
6.42
USD
|
+1.74%
|
|
-0.93%
|
+3.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
644
|
583.9
|
124
|
534.3
|
1,439
|
1,494
|
-
|
-
|
Enterprise Value (EV)
1 |
445.3
|
583.9
|
124
|
534.3
|
1,439
|
1,494
|
1,494
|
1,494
|
P/E ratio
|
-5.11
x
|
-6.16
x
|
-0.72
x
|
-6.79
x
|
-20.7
x
|
-14.3
x
|
233
x
|
9.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
122
x
|
77.1
x
|
12.3
x
|
10.2
x
|
11.6
x
|
7.15
x
|
4.07
x
|
2.65
x
|
EV / Revenue
|
122
x
|
77.1
x
|
12.3
x
|
10.2
x
|
11.6
x
|
7.15
x
|
4.07
x
|
2.65
x
|
EV / EBITDA
|
-7.26
x
|
-6.56
x
|
-0.88
x
|
-10.3
x
|
-29.7
x
|
-26.8
x
|
15.9
x
|
6.26
x
|
EV / FCF
|
-8.38
x
|
-7.14
x
|
-0.8
x
|
-7.62
x
|
-
|
-20.5
x
|
-1,057
x
|
8.69
x
|
FCF Yield
|
-11.9%
|
-14%
|
-125%
|
-13.1%
|
-
|
-4.88%
|
-0.09%
|
11.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
85,807
|
90,248
|
112,743
|
187,460
|
232,138
|
232,686
|
-
|
-
|
Reference price
2 |
7.505
|
6.470
|
1.100
|
2.850
|
6.200
|
6.420
|
6.420
|
6.420
|
Announcement Date
|
3/6/20
|
3/8/21
|
2/28/22
|
3/2/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.281
|
7.571
|
10.1
|
52.16
|
124.5
|
208.8
|
367
|
563.1
|
EBITDA
1 |
-88.76
|
-88.96
|
-140.2
|
-51.86
|
-48.45
|
-55.76
|
94.07
|
238.5
|
EBIT
1 |
-91.26
|
-90.78
|
-154.3
|
-63.76
|
-63.28
|
-103.7
|
19.3
|
173.4
|
Operating Margin
|
-1,728.14%
|
-1,199.05%
|
-1,528.63%
|
-122.24%
|
-50.84%
|
-49.69%
|
5.26%
|
30.79%
|
Earnings before Tax (EBT)
1 |
-94.94
|
-94.31
|
-158.2
|
-67.2
|
-65.52
|
-108
|
4.189
|
169.6
|
Net income
1 |
-94.94
|
-94.31
|
-158.2
|
-67.21
|
-66.07
|
-106.8
|
6.787
|
167.7
|
Net margin
|
-1,797.77%
|
-1,245.71%
|
-1,566.46%
|
-128.85%
|
-53.08%
|
-51.13%
|
1.85%
|
29.79%
|
EPS
2 |
-1.470
|
-1.050
|
-1.520
|
-0.4200
|
-0.3000
|
-0.4489
|
0.0275
|
0.6543
|
Free Cash Flow
1 |
-76.81
|
-81.76
|
-154.4
|
-70.1
|
-
|
-72.84
|
-1.413
|
172
|
FCF margin
|
-1,454.44%
|
-1,079.9%
|
-1,529.35%
|
-134.4%
|
-
|
-34.89%
|
-0.38%
|
30.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
72.1%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
102.53%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/8/21
|
2/28/22
|
3/2/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.173
|
1.029
|
0.468
|
2.526
|
4.986
|
44.18
|
11.37
|
22.33
|
56.39
|
34.36
|
35.81
|
46.97
|
56.88
|
67.61
|
75.83
|
EBITDA
1 |
-39.51
|
-31.45
|
-23.68
|
-22.73
|
-19.63
|
14.18
|
-23.15
|
-13.42
|
11.18
|
-23.69
|
-23.25
|
-15.08
|
-13.11
|
-4.317
|
2.666
|
EBIT
1 |
-42.24
|
-35.27
|
-27.81
|
-26.22
|
-21.88
|
12.14
|
-26.06
|
-16.62
|
7.398
|
-27.99
|
-33.57
|
-28.7
|
-24.59
|
-16.93
|
-11.37
|
Operating Margin
|
-3,600.68%
|
-3,427.89%
|
-5,941.67%
|
-1,037.81%
|
-438.83%
|
27.49%
|
-229.25%
|
-74.44%
|
13.12%
|
-81.44%
|
-93.73%
|
-61.1%
|
-43.23%
|
-25.04%
|
-14.99%
|
Earnings before Tax (EBT)
1 |
-43.59
|
-36.23
|
-28.07
|
-26.93
|
-22.89
|
10.7
|
-26.76
|
-17.12
|
6.829
|
-28.47
|
-34.5
|
-29.77
|
-25.68
|
-18.02
|
-12.27
|
Net income
1 |
-43.59
|
-36.23
|
-28.07
|
-26.94
|
-22.89
|
10.7
|
-26.77
|
-17.12
|
6.629
|
-28.8
|
-34.26
|
-29.6
|
-25.1
|
-17.79
|
-12.56
|
Net margin
|
-3,715.86%
|
-3,521.28%
|
-5,998.08%
|
-1,066.43%
|
-459.15%
|
24.21%
|
-235.49%
|
-76.66%
|
11.76%
|
-83.82%
|
-95.66%
|
-63.01%
|
-44.13%
|
-26.32%
|
-16.56%
|
EPS
2 |
-0.4200
|
-0.3100
|
-0.2100
|
-0.1900
|
-0.1400
|
0.0600
|
-0.1300
|
-0.0800
|
0.0300
|
-0.1200
|
-0.1478
|
-0.1256
|
-0.1056
|
-0.0711
|
-0.0533
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
2/28/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/3/23
|
8/2/23
|
10/31/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
199
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-76.8
|
-81.8
|
-154
|
-70.1
|
-
|
-72.8
|
-1.41
|
172
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-152%
|
-74.3%
|
-49.8%
|
-24.6%
|
42.9%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.33
|
0.32
|
1.87
|
0.06
|
0.34
|
1.09
|
1.1
|
1.11
|
Capex / Sales
|
6.15%
|
4.28%
|
18.49%
|
0.11%
|
0.28%
|
0.52%
|
0.3%
|
0.2%
|
Announcement Date
|
3/6/20
|
3/8/21
|
2/28/22
|
3/2/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
6.42
USD Average target price
13.5
USD Spread / Average Target +110.28% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.55% | 1.49B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|